NCT01967576View on ClinicalTrials.gov

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 19, 2013

Primary Completion Date

June 29, 2015

Study Completion Date

December 1, 2020

Conditions
PheochromocytomaParaganglioma
Interventions
DRUG

Axitinib (AG-013736)

5 mg twice a day on a 28-day cycle.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01967576 - Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma | Biotech Hunter | Biotech Hunter